

Product Information	
Catalog No.	BS10735
Product name	Anti-Human Angiopoietin-2 Reference Antibody (Zansecimab, RUO)
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species reactivity	Human
Host species	Humanized
Clonality	Monoclonal
Isotype	IgG4-Kappa
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	1mg/ml
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Target	ANG-2, ANGPT2, Angiopoietin-2
Expression system	Mammalian Cells
Accession	O15123
Endotoxin level	Please contact the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative Names	LY-3127804, LY3127804, 2415205-37-5
Note	For research use only. Not suitable for clinical or therapeutic use.


Background

Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity.

- Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology., PMID:31108880
- Acute respiratory distress syndrome., PMID:30872586
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials., PMID:38158159
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials., PMID:35085502
- Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials., PMID:38280653
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2., PMID:38382813
- Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial., PMID:30905643

- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials., PMID:35085503
- Blocking the angiopoietin-2-dependent integrin β -1 signaling axis abrogates small cell lung cancer invasion and metastasis., PMID:38775153
- Loss of TGF β -Mediated Repression of Angiopoietin-2 in Pericytes Underlies Germinal Matrix Hemorrhage Pathogenesis., PMID:39129597

Image Data



SDS-PAGE for Research Grade Zanseximab

SDS-PAGE